Home - Invivoscribe

Products & Clinical Lab Services

Invivoscribe

PRODUCTS & CLINICAL LAB SERVICES

Cat #: 93080010
IdentiClone^® BCL1/J_H Translocation Assay – Gel Detection
SUMMARY AND EXPLANATION OF THE TEST The BCL1/JH t(11;14)(q13;q32) gene translocation is mainly found in mantle cell lymphoma (MCL) (50-70%), but is a...
View Product
Cat #: 93080020
IdentiClone^® BCL1/J_H Translocation Assay MegaKit – Gel Detection
The BCL1/JH t(11;14)(q13;q32) gene translocation is mainly found in mantle cell lymphoma (MCL) (50-70%), but is also seen in B-prolymphocytic leukemi...
View Product
Cat #: 93090020
IdentiClone^® BCL2/J_H Translocation Assay – Gel Detection
The BCL2 t(14;18) (q32;q21) translocation is found in 80-90% of follicular lymphomas and 30% of diffuse large cell lymphomas; however, this translocat...
View Product
Cat #: 93090040
IdentiClone^® BCL2/J_H Translocation Assay MegaKit – Gel Detection
The BCL2 t(14;18) (q32;q21) translocation is found in 80-90% of follicular lymphomas and 30% of diffuse large cell lymphomas; however, this translocat...
View Product
Cat #: 91000010
IdentiClone^® IGH + IGK B-Cell Clonality Assay – Gel Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products that are uniq...
View Product
Cat #: 91010020
IdentiClone^® IGH Gene Clonality Assay – Gel Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products that are uniq...
View Product
Cat #: 91010040
IdentiClone^® IGH Gene Clonality Assay MegaKit – Gel Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products that are uniq...
View Product
Cat #: 91020020
IdentiClone^® IGK Gene Clonality Assay – Gel Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products that are uniq...
View Product
Cat #: 91020030
IdentiClone^® IGK Gene Clonality Assay MegaKit – Gel Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products that are uniq...
View Product
Cat #: 91030010
IdentiClone^® IGL Gene Clonality Assay – Gel Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products that are uniq...
View Product
Cat #: 92050010
IdentiClone^® TCRB Gene Clonality Assay – Gel Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products that are uniq...
View Product
Cat #: 92050020
IdentiClone^® TCRB Gene Clonality Assay MegaKit – Gel Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products that are uniq...
View Product
Cat #: 92060010
IdentiClone^® TCRD Gene Clonality Assay – Gel Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products that are uniq...
View Product
Cat #: 94120010
LeukoStrat^® FLT3 Mutation Assay – Gel Detection
Acute myeloid leukemia (AML) in general has a poor prognosis. Assessment of the mutation status of the FLT3 (fms-like tyrosine kinase 3) receptor gene...
View Product
Cat #: 94120020
LeukoStrat^® FLT3 Mutation Assay MegaKit – Gel Detection
Acute myeloid leukemia (AML) in general has a poor prognosis. Assessment of the mutation status of the FLT3 (fms-like tyrosine kinase 3) receptor gene...
View Product

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

PRODUCTS & CLINICAL LAB SERVICES

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

PRODUCTS & CLINICAL LAB SERVICES

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing